A Self-Immunoregulatory Nanosensitizer for Sonodynamic Cancer Therapy.

Authors

Jiahao Liu, Zaigang Zhou, Cheng Li, Wei Xiong, Huan Ding, Sheng Wu, Zhengxiang Wang, Long Wang, Jianliang Shen

Published in

Advanced materials (Deerfield Beach, Fla.). Pages e73775. Jun 19, 2026. Epub Jun 19, 2026.

Abstract

Sonodynamic therapy (SDT) generates reactive oxygen species (ROS) for noninvasive, spatiotemporally controlled tumor therapy. However, whether ROS-driven stress also reprograms tumor immune signaling toward immune resistance, thereby limiting durable antitumor immunity, remains unclear. This study reveals that immune resistance is a universal mechanism shared by three major classes of clinically used SDT sensitizers. A porphyrin-biguanide-loaded albumin nanoparticle (POR-BG@Alb) is rationally developed as a self-immunoregulatory sonosensitizer, which induces mitochondrial dysfunction to activate AMP-activated protein kinase (AMPK) and suppress c-MYC, concomitantly downregulating PD-L1 and CD47 and enhancing T-cell killing and macrophage phagocytosis. Unlike clinically used traditional sensitizers that upregulate PD-L1/CD47 after SDT and promote innate and adaptive immunosuppression, POR-BG@Alb amplifies sonodynamic efficacy while limiting this feedback. Across orthotopic bladder cancer, subcutaneous xenograft, and orthotopic breast cancer models, POR-BG@Alb-mediated SDT suppresses primary tumors, elicits abscopal antimetastatic effects, establishes immune memory, and extends median survival in subcutaneous xenografts from 17 to 44 days. Collectively, this research unmasks a previously unappreciated role of SDT in inducing immune resistance and shows that POR-BG@Alb integrates potent sonodynamic activity with self-oxygen regulation and self-immunoregulation to enable durable systemic antitumor immunity, providing a promising nanotherapeutic strategy for SDT clinical translation.

PMID:
42322055
Bibliographic data and abstract were imported from PubMed on 20 Jun 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.